The role of patient-based treatment planning in peptide receptor radionuclide therapy

详细信息    查看全文

• 作者：Deni Hardiansyah ; Christian Maass…
• 关键词：PRRT ; PBPK modeling ; Treatment planning ; PET
• 刊名：European Journal of Nuclear Medicine and Molecular Imaging
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：43
• 期：5
• 页码：871-880
• 全文大小：484 KB
• 参考文献：1.de Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, et al. 90Yttrium and 111Indium labelling, receptor binding and biodistribution of [DOTA0, d-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med. 1997;24:368–71.PubMed
  2.Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10 Suppl 2:S23–9.CrossRef PubMed
  3.Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med. 1997;24:792–5.PubMed
  4.Rolleman EJ, Melis M, Valkema R, Boerman OC, Krenning EP, de Jong M. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging. 2010;37:1018–31.CrossRef PubMed
  5.Cremonesi M, Botta F, Di Dia A, Ferrari M, Bodei L, De Cicco C, et al. Dosimetry for treatment with radiolabelled somatostatin analogues. A review. Q J Nucl Med Mol Imaging. 2010;54:37–51.PubMed
  6.Cremonesi M, Ferrari M, Di Dia A, Botta F, De Cicco C, Bodei L, et al. Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy. Q J Nucl Med Mol Imaging. 2011;55:155–67.PubMed
  7.Glatting G, Bardiès M, Lassmann M. Treatment planning in molecular radiotherapy. Z Med Phys. 2013;23:262–9.CrossRef PubMed
  8.Kletting P, Bunjes D, Reske SN, Glatting G. Improving anti-CD45 antibody radioimmunotherapy using a physiologically based pharmacokinetic model. J Nucl Med. 2009;50:296–302.CrossRef PubMed
  9.Thomas SR. Options for radionuclide therapy: from fixed activity to patient-specific treatment planning. Cancer Biother Radiopharm. 2002;17:71–82.CrossRef PubMed
  10.Marincek N, Jorg AC, Brunner P, Schindler C, Koller MT, Rochlitz C, et al. Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study. J Transl Med. 2013;11:17–27.CrossRef PubMed PubMedCentral
  11.Kletting P, Kull T, Bunjes D, Luster M, Reske SN, Glatting G. Optimal preloading in radioimmunotherapy with anti-CD45 antibody. Med Phys. 2011;38:2572–8.CrossRef PubMed
  12.Lassmann M, Chiesa C, Flux G, Bardies M, Committee ED. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging. 2011;38:192–200.CrossRef PubMed
  13.Strigari L, Konijnenberg M, Chiesa C, Bardies M, Du Y, Gleisner KS, et al. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging. 2014;41:1976–88.CrossRef PubMed
  14.Mansi L, Cuccurullo V. Diagnostic imaging in neuroendocrine tumors. J Nucl Med. 2014;55:1576–7.CrossRef PubMed
  15.Kletting P, Kull T, Bunjes D, Mahren B, Luster M, Reske SN, et al. Radioimmunotherapy with anti-CD66 antibody: improving the biodistribution using a physiologically based pharmacokinetic model. J Nucl Med. 2010;51:484–91.CrossRef PubMed
  16.Kletting P, Müller B, Erentok B, Schmaljohann J, Behrendt FF, Reske SN, et al. Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy. Med Phys. 2012;39:5708–17.CrossRef PubMed
  17.Bradshaw-Pierce EL, Eckhardt SG, Gustafson DL. A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res. 2007;13:2768–76.CrossRef PubMed
  18.Heatherington AC, Vicini P, Golde H. A pharmacokinetic/pharmacodynamic comparison of SAAM II and PC/WinNonlin modeling software. J Pharm Sci. 1998;87:1255–63.CrossRef PubMed
  19.Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med. 2006;47:1467–75.PubMed
  20.Chalkia MT, Stefanoyiannis AP, Chatziioannou SN, Round WH, Efstathopoulos EP, Nikiforidis GC. Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review. Australas Phys Eng Sci Med. 2015;38:7–22.CrossRef PubMed
  21.Tsougos I, Loudos G, Georgoulias P, Theodorou K, Kappas C. Patient-specific internal radionuclide dosimetry. Nucl Med Commun. 2010;31:97–106.CrossRef PubMed
  22.Garkavij M, Nickel M, Sjogreen-Gleisner K, Ljungberg M, Ohlsson T, Wingardh K, et al. 177Lu-[DOTA0, Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116:1084–92.CrossRef PubMed
  23.Glatting G, Landmann M, Kull T, Wunderlich A, Blumstein NM, Buck AK, et al. Internal radionuclide therapy: the ULMDOS software for treatment planning. Med Phys. 2005;32:2399–405.CrossRef PubMed
  24.Barrett PH, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, et al. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism. 1998;47:484–92.CrossRef PubMed
  25.Snyder WS, Cook MJ, Nasset ES, Karhausen RS, Howells GP. Report of the task group on reference man. Ann ICRP. 1979;3:iii.
  26.Durkee BY, Mudd SR, Roen CN, Clipson L, Newton MA, Weichert JP, et al. Reproducibility of tumor volume measurement at microCT colonography in living mice. Acad Radiol. 2008;15:334–41.CrossRef PubMed PubMedCentral
  27.Miller TR, Grigsby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys. 2002;53:353–9.CrossRef PubMed
  28.Chase DM, Sill MW, Monk BJ, Chambers MD, Darcy KM, Han ES, et al. Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study. Gynecol Oncol. 2012;126:375–80.CrossRef PubMed
  29.Sugawara Y, Murase K, Kikuchi K, Sakayama K, Miyazaki T, Kajihara M, et al. Measurement of tumor blood flow using dynamic contrast-enhanced magnetic resonance imaging and deconvolution analysis: a preliminary study in musculoskeletal tumors. J Comput Assist Tomogr. 2006;30:983–90.CrossRef PubMed
  30.Edwards WB, Fields CG, Anderson CJ, Pajeau TS, Welch MJ, Fields GB. Generally applicable, convenient solid-phase synthesis and receptor affinities of octreotide analogs. J Med Chem. 1994;37:3749–57.CrossRef PubMed
  31.Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–82.CrossRef PubMed
  32.Svensson J, Berg G, Wangberg B, Larsson M, Forssell-Aronsson E, Bernhardt P. Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment. Eur J Nucl Med Mol Imaging. 2015;42:947–55.CrossRef PubMed PubMedCentral
  33.Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5–19.CrossRef PubMed
  34.Harris A, Kamishima T, Hao HY, Kato F, Omatsu T, Onodera Y, et al. Splenic volume measurements on computed tomography utilizing automatically contouring software and its relationship with age, gender, and anthropometric parameters. Eur J Radiol. 2010;75:e97–101.CrossRef PubMed
  35.Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl. 2005;11:1481–93.CrossRef PubMed
  36.Leggett RW, Williams LR. A proposed blood circulation model for reference man. Health Phys. 1995;69:187–201.CrossRef PubMed
  37.Thomas GD, Chappell MJ, Dykes PW, Ramsden DB, Godfrey KR, Ellis JR, et al. Effect of dose, molecular size, affinity, and protein binding on tumor uptake of antibody or ligand: a biomathematical model. Cancer Res. 1989;49:3290–6.PubMed
  38.Vegt E, de Jong M, Wetzels JF, Masereeuw R, Melis M, Oyen WJ, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med. 2010;51:1049–58.CrossRef PubMed
  39.Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, et al. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Eur J Nucl Med Mol Imaging. 2013;40:514–23.CrossRef PubMed
  40.Hänscheid H, Sweeney RA, Flentje M, Buck AK, Lohr M, Samnick S, et al. PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma. Eur J Nucl Med Mol Imaging. 2012;39:1284–8.CrossRef PubMed
  41.Lyra M, Lagopati N, Charalambatou P, Vamvakas I. Patient-specific dosimetry in radionuclide therapy. Radiat Prot Dosim. 2011;147:258–63.CrossRef
  42.Walrand S, Barone R, Pauwels S, Jamar F. Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts. Eur J Nucl Med Mol Imaging. 2011;38:1270–80.CrossRef PubMed
  43.Hindorf C, Glatting G, Chiesa C, Linden O, Flux G, Committee ED. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37:1238–50.CrossRef PubMed
  44.Oomen SP, Hofland LJ, van Hagen PM, Lamberts SW, Touw IP. Somatostatin receptors in the haematopoietic system. Eur J Endocrinol. 2000;143 Suppl 1:S9–14.CrossRef PubMed
  45.Peluso G, Mansi L. Immunity and somatostatin receptors. Minerva Endocrinol. 2001;26:111–7.PubMed
  46.Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0), Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging. 2009;36:1138–46.CrossRef PubMed PubMedCentral
  47.Pereira JM, Stabin MG, Lima FR, Guimaraes MI, Forrester JW. Image quantification for radiation dose calculations—limitations and uncertainties. Health Phys. 2010;99:688–701.
  
• 作者单位：Deni Hardiansyah (1) (2)
  Christian Maass (1)
  Ali Asgar Attarwala (1) (2)
  Berthold Müller (3)
  Peter Kletting (4)
  Felix M. Mottaghy (3) (5)
  Gerhard Glatting (1)
  
  1. Medical Radiation Physics/Radiation Protection, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
  2. Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
  3. Klinik für Nuklearmedizin, University Hospital, RWTH Aachen University, Aachen, Germany
  4. Klinik für Nuklearmedizin, Universität Ulm, Ulm, Germany
  5. Department of Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Nuclear Medicine
  Imaging and Radiology
  Orthopedics
  Cardiology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1619-7089

文摘

Background Accurate treatment planning is recommended in peptide-receptor radionuclide therapy (PRRT) to minimize the toxicity to organs at risk while maximizing tumor cell sterilization. The aim of this study was to quantify the effect of different degrees of individualization on the prediction accuracy of individual therapeutic biodistributions in patients with neuroendocrine tumors (NETs).